In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Carson to control more than a third of ethnic hair care market share after Johnson buy.

This article was originally published in The Rose Sheet

Executive Summary

CARSON TO CONTROL 35% OF ETHNIC HAIR CARE MARKET following its acquisition of Johnson Products, giving the firm the number one market share spot in all ethnic hair care categories, Carson President and Chief Operating Officer Joyce Roche said during a conference call with securities analysts June 18. The purchase of the mass market personal care business from IVX Bioscience (formerly Ivax) puts Carson 10 points ahead of the competition in hair relaxers, the largest ethnic hair care category in terms of market share, and gives the company a presence in the smaller hair care maintenance categories, Roche noted. Johnson Products markets eponymous offerings, as well as the Gentle Treatment, Ultra Sheen, Precise, Bantu and Afro Sheen brands.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel